Antifungal Drugs

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F20%3A00523473" target="_blank" >RIV/61388971:_____/20:00523473 - isvavai.cz</a>
Result on the web
<a href="https://www.mdpi.com/2218-1989/10/3/106" target="_blank" >https://www.mdpi.com/2218-1989/10/3/106</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/metabo10030106" target="_blank" >10.3390/metabo10030106</a>

Result language
angličtina
Original language name
Antifungal Drugs
Original language description
We reviewed the licensed antifungal drugs and summarized their mechanisms of action, pharmacological profiles, and susceptibility to specific fungi. Approved antimycotics inhibit 1,3-beta-d-glucan synthase, lanosterol 14-alfa-demethylase, protein, and deoxyribonucleic acid biosynthesis, or sequestrate ergosterol. Their most severe side effects are hepatotoxicity, nephrotoxicity, and myelotoxicity. Whereas triazoles exhibit the most significant drug-drug interactions, echinocandins exhibit almost none. The antifungal resistance may be developed across most pathogens and includes drug target overexpression, efflux pump activation, and amino acid substitution. The experimental antifungal drugs in clinical trials are also reviewed. Siderophores in the Trojan horse approach or the application of siderophore biosynthesis enzyme inhibitors represent the most promising emerging antifungal therapies.
Czech name
—
Czech description
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)